Cellectis S.A. - American Depositary Shares (CLLS) Covered Calls
You can sell covered calls on Cellectis S.A. - American Depositary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CLLS (prices last updated Tue 4:16 PM ET):
Cellectis S.A. - American Depositary Shares (CLLS) Stock Quote | ||||||
---|---|---|---|---|---|---|
Last | Change | Bid | Ask | Volume | P/E | Market Cap |
2.21 | +0.01 | 2.13 | 2.42 | 11K | - | 0.0 |
Covered Calls For Cellectis S.A. - American Depositary Shares (CLLS) | ||||||
---|---|---|---|---|---|---|
Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
Oct 18 | 2.5 | 0.00 | 2.42 | 0.0% | 0.0% | |
Nov 15 | 2.5 | 0.05 | 2.37 | 2.1% | 14.5% | |
Subscribers get access to the full covered call chain, and more features. |
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France
Top 10 Open Interest For Oct 18 Expiration | Top 5 High Yield | |||||
---|---|---|---|---|---|---|
1. | NVDA covered calls | 6. | SLV covered calls | 1. | CPRI covered calls | |
2. | IWM covered calls | 7. | EEM covered calls | 2. | DJT covered calls | |
3. | SPY covered calls | 8. | TLT covered calls | 3. | MBLY covered calls | |
4. | QQQ covered calls | 9. | GLD covered calls | 4. | SMMT covered calls | |
5. | HYG covered calls | 10. | AAPL covered calls | 5. | CLSK covered calls |
Want more examples? CLIX Covered Calls | CLMT Covered Calls